Alzheimer's disease is characterized by extensive cerebral amyloid depositi
on. Amyloid deposits associated with damaged neuropil and blood vessels con
tain abundant fibrils formed by the amyloid beta-protein (A beta). Fibrils,
both in vitro and in vivo, are neurotoxic. For this reason, substantial ef
fort has been expended to develop therapeutic approaches to control A beta
production and amyloidogenesis. Achievement of the latter goal is facilitat
ed by a rigorous mechanistic understanding of the fibrillogenesis process.
Recently, we discovered a novel intermediate in the pathway of A beta fibri
l formation, the amyloid protofibril (Walsh, D, RI,, Lomakin, A., Benedek,
G. B., Condron, RI. Ri,, and Teplow, D. B. (1997) J. Biol. Chem. 272-, 2236
4-22372). We report here results of studies of the assembly, structure, and
biological activity of these polymers. We find that protofibrils: 1) are i
n equilibrium with low molecular weight A beta (monomeric or dimeric); 2) h
ave a secondary structure characteristic of amyloid fibrils; 3) appear as b
eaded chains in rotary shadowed preparations examined electron microscopica
lly; 4) give rise to mature amyloid-like fibrils; and 5) affect the normal
metabolism of cultured neurons. The implications of these results for the d
evelopment of therapies for Alzheimer's disease and for our understanding o
f fibril assembly are discussed.